-
A
Experimental timelines.
-
B
Expression of CD39 in the hippocampus of mice injected with CD200Fc (n = 6 mice/group; CD39Fc versus IgG, P = 0.0004, Student's t‐test).
-
C
Time in the interaction zone of mice infusion with CD39Fc after knockdown of CD39 in SI test (n = 13, 14, 16, 11 mice; Interaction, F
3,100 = 2.977, P = 0.0352; Target, F
1,100 = 6.175, P = 0.0146; Drug, F
3,100 = 2.028, P = 0.1148; for target, CSDS‐LV‐GFP‐IgG versus Ctrl‐LV‐GFP‐IgG, P = 0.0077; CSDS‐LV‐siCD39‐IgG versus CSDS‐LV‐GFP‐IgG, P = 0.0031; CSDS‐LV‐siCD39‐CD39Fc versus CSDS‐LV‐siCD39‐IgG, P = 0.0378, two‐way ANOVA with Tukey's post‐test).
-
D
Social interaction ratio of mice infusion with CD39Fc after knockdown of CD39 in SI test (n = 13, 14, 16, 11 mice; Treatment, F
3,50 = 5.690, P = 0.0020; CSDS‐LV‐GFP‐IgG versus Ctrl‐LV‐GFP‐IgG, P = 0.0012; CSDS‐LV‐siCD39‐IgG versus CSDS‐LV‐GFP‐IgG, P = 0075; CSDS‐LV‐siCD39‐CD39Fc versus CSDS‐LV‐siCD39‐IgG, P = 0.0263, one‐way ANOVA with Fisher's LSD test).
-
E, F
Infusion with CD39Fc into hippocampus abolished the decreased immobility time of stressed mice injection with LV‐siCD39 in the TST (E) and FST (F) (for TST, n = 13, 14, 13, 11; Treatment, F
3,47 = 13.22, P < 0.0001; CSDS‐LV‐GFP‐IgG versus Ctrl‐LV‐GFP‐IgG, P < 0.0001; CSDS‐LV‐siCD39‐IgG versus CSDS‐LV‐GFP‐IgG, P < 0001; CSDS‐LV‐siCD39‐CD39Fc versus CSDS‐LV‐siCD39‐IgG, P = 0.05; for FST, n = 13, 14, 16, 11; Treatment, F
3,50 = 4.047, P = 0.0119; CSDS‐LV‐GFP‐IgG versus Ctrl‐LV‐GFP‐IgG, P = 0.0116; CSDS‐LV‐siCD39‐IgG versus CSDS‐LV‐GFP‐IgG, P = 0191; CSDS‐LV‐siCD39‐CD39Fc versus CSDS‐LV‐siCD39‐IgG, P = 0.0261, one‐way ANOVA with Fisher's LSD test).
-
G
Total distance of mice in the OFT (n = 14, 14, 15, 11 mice; Treatment, F
3,50 = 1.136, P = 0.3437, one‐way ANOVA with Fisher's LSD test).
Data information: Data are expressed as the means ± SEM. *
< 0.001.